Share on LinkedInShare on LinkedIn

ARTICLE · 08 MARCH 2023

Generic's Conversion From Paragraph IV To Section Viii Upends Subject Matter Jurisdiction On Declaratory Judgment Counterclaims

Akin
Akin
Contributor
Akin

Akin

Akin is a global law firm with more than 1,100 lawyers and advisors who pride themselves on...

View firm profile
Explore more from Akin

The District Court of Delaware dismissed a generic drug company's declaratory judgment counterclaims of non-infringement and invalidity, finding that the court no longer...

United StatesIntellectual Property

The District Court of Delaware dismissed a generic drug company's declaratory judgment counterclaims of non-infringement and invalidity, finding that the court no longer had subject matter jurisdiction after the generic company converted its Paragraph IV certification to a Section viii statement.

The generic company initially submitted its Abbreviated New Drug Application ("ANDA") seeking FDA approval for a generic version of Entresto® with certifications pursuant to 35 U.S.C. § 355(j)(2)(A)(vii)(IV) ("Paragraph IV certifications"), stating that its generic version would not infringe the listed patents or that those patents are not enforceable. The patent owner promptly asserted infringement claims for three method of use patents against the generic company, and the generic filed declaratory judgement counterclaims of non-infringement and invalidity of the asserted patents.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from